Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the addition of a new preclinical candidate, APVO455, to its portfolio of CD3-directed therapeutics. This development expands Aptevo's focus from hematologic cancers to include solid tumors. APVO455 targets Nectin-4+ cancers and joins other molecules in Aptevo's CD3 suite, which includes mipletamig, currently in Phase 1b/2 trials for acute myeloid leukemia $(AML.AU)$, and APVO442, in preclinical development for prostate cancer. The company reports that mipletamig has shown promising results, with 85% remission rates in combination with standard care for AML and no observed cytokine release syndrome in early trial cohorts. The results of APVO455's preclinical studies have not yet been presented, but Aptevo's CEO, Marvin White, expressed confidence in the candidate's potential, citing the favorable safety profile observed in the mipletamig trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.